Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

SpeedWeed

AUGUST 11, 2021

With a goal of determining the “the efficacy of marijuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”. We overcame significant regulatory obstacles obstructing cannabis research to conduct the first clinical trial of inhaled cannabis for PTSD ,” said Yazar-Klosinki. .

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. Drug Enforcement Agency (DEA). This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

AUGUST 18, 2022

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Tweet this. However, change appears imminent. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Also in November, it reported positive data on its standout IND, CYB003. It’s also initiating phase 2a clinical trial into conditions such as eating disorders and fibromyalgia.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Veriheal

AUGUST 31, 2020

Data shows that Hispanic Americans are more interested in using cannabis and CBD for wellness than other groups and “is believed to be in part due to the connections between the Hispanic community and nature.” Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” .

Research and Development 117

Research and Development Education Agriculture Patients 117